TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
PYC Therapeutics Limited ( (AU:PYC) ) has provided an announcement.
PYC Therapeutics Limited has announced promising results from its ongoing Phase 1/2 clinical trials of VP-001, an investigational drug candidate for Retinitis Pigmentosa type 11 (RP11). Patients treated with VP-001 have shown sustained improvements in vision and retinal sensitivity up to 18 months post-treatment, with the treated eyes outperforming untreated eyes and a natural history control group across all measured endpoints. The drug has demonstrated a favorable safety profile with no serious adverse events reported, and PYC is preparing to engage with the US FDA to design a registrational trial expected to commence in 2026.
The most recent analyst rating on (AU:PYC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a precision medicine company focused on developing treatments for genetic diseases that currently have no available options. The company is engaged in three clinical-stage drug development programs, with a particular focus on VP-001, a drug candidate targeting Retinitis Pigmentosa type 11 (RP11), a blinding eye disease caused by a genetic mutation.
Average Trading Volume: 700,755
Technical Sentiment Signal: Hold
Current Market Cap: A$694.1M
See more data about PYC stock on TipRanks’ Stock Analysis page.